Stanley L. Garnett and Carrie E. Johnson of Brownstein Hyatt Farber Schreck have stepped in as defense counsel to radiopharmaceutical drug developer Cell>Point and its founders Greg R. Colip and Terry A. Colip in a pending SEC enforcement action. The complaint, filed June 10 in Colorado District Court, accuses the defendants of misleading investors regarding the status of the company's clinical trials. The case, assigned to U.S. District Judge Philip A. Brimmer, is 1:21-cv-01574, U.S. Securities and Exchange Commission v. Cell>Point, LLC et al.